EntreMed, Inc. ENMD, a
clinical-stage pharmaceutical company developing therapeutics for the
treatment of a variety of cancers, announced today the commencement of a
multi-center Phase 2 study entitled "Phase II Study of Oral ENMD-2076
Administered to Patients with Ovarian Clear Cell Carcinomas." The study is
led by principal investigator Amit M. Oza, MD at Princess Margaret Cancer
Centre in Toronto, Canada with participation of up to seven additional cancer
centers in Canada and the United States. More information about the clinical
trial can be found at www.clinicaltrials.gov.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in